Gelonghui November 27丨Guangshengtang (300436.SZ) announced that recently, Fujian Guangshengtang Pharmaceutical Co., Ltd. received the “Drug Registration Certificate” approved and issued by the State Drug Administration regarding the company's central drug for curing hepatitis C, solifosbuvir tablets (valgandine). The approval of solifosbuvir tablets for marketing and production will further improve the company's product layout in the field of liver health, strengthen its market share and leading position in the field of liver medicine, build the company's “liver disease expert” series brand, provide the company with new growth points, and help the company innovate, transform and develop.
广生堂(300436.SZ)：治愈丙肝核心药物索磷布韦片(丙甘定)获得药品生产注册批准
Guangshengtang (300436.SZ): Solofovir tablets (progandine), the core drug for curing hepatitis C, obtained drug production registration approval
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.